Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 279890, 13 pages
http://dx.doi.org/10.1155/2015/279890
Research Article

Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt

1Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Centre, Edifício Egas Moniz, Avenida Prof. Egas Moniz, 1649-028 Lisboa, Portugal
2Rheumatology Department, Hospital de Santa Maria, Lisbon Academic Medical Centre, Avenida Prof. Egas Moniz, 1649-028 Lisboa, Portugal
3Rheumatology Department, Hospital Garcia de Orta, Avenida Prof. Torrado da Silva, 2801-951 Almada, Portugal
4Rheumatology Department, Centro Hospitalar Universitário de Coimbra, Praceta Mota Pinto, 3000-076 Coimbra, Portugal
5Rheumatology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, Rua da Junqueira 126, 1349-019 Lisboa, Portugal
6Rheumatology Department, Instituto Português de Reumatologia, R. Beneficência 7, 1050-034 Lisboa, Portugal
7Rheumatology Department, Unidade Local de Saúde do Alto Minho, Hospital Conde de Bertiandos, Largo Conde de Bertiandos, 4990-041 Ponte de Lima, Portugal
8Rheumatology Department, Centro Hospitalar São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
9CEDOC, NOVA Medical School, Nova University, Campo dos Mártires da Pátria 130, 1169-056 Lisboa, Portugal

Received 5 December 2014; Accepted 11 February 2015

Academic Editor: Guixiu Shi

Copyright © 2015 Vasco C. Romão et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. C. Taylor and M. Feldmann, “Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 5, no. 10, pp. 578–582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. C. Hochberg, J. K. Tracy, M. Hawkins-Holt, and R. H. Flores, “Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, Supplement 2, pp. 13–16, 2003. View at Google Scholar · View at Scopus
  3. K. J. Aaltonen, L. M. Virkki, A. Malmivaara, Y. T. Konttinen, D. C. Nordström, and M. Blom, “Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis,” PLoS ONE, vol. 7, no. 1, Article ID e30275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Canhão, A. M. Rodrigues, A. F. Mourão et al., “Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis,” Rheumatology, vol. 51, no. 11, Article ID kes184, pp. 2020–2026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Greenberg, G. Reed, D. Decktor et al., “A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry,” Annals of the Rheumatic Diseases, vol. 71, no. 7, pp. 1134–1142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. L. Hyrich, K. D. Watson, A. J. Silman, and D. P. M. Symmons, “Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register,” Rheumatology, vol. 45, no. 12, pp. 1558–1565, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Smolen, R. Landewé, F. C. Breedveld et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update,” Annals of the Rheumatic Diseases, vol. 73, no. 3, pp. 492–509, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. E. Fonseca, M. Bernardes, H. Canhão et al., “Portuguese guide lines for the use of biological agents in rheumatoid arthritis—october 2011 update,” Acta Reumatologica Portuguesa, vol. 36, no. 4, pp. 385–388, 2011. View at Google Scholar · View at Scopus
  9. I. Flouri, T. E. Markatseli, P. V. Voulgari et al., “Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival,” Seminars in Arthritis and Rheumatism, vol. 43, no. 4, pp. 447–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Markenson, A. Gibofsky, W. R. Palmer et al., “Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry,” The Journal of Rheumatology, vol. 38, no. 7, pp. 1273–1281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Salliot, A. Finckh, W. Katchamart et al., “Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis,” Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 266–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Schoels, D. Aletaha, J. S. Smolen, and J. B. Wong, “Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis,” Annals of the Rheumatic Diseases, vol. 71, no. 8, pp. 1303–1308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dougados, K. Kissel, T. Sheeran et al., “Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY),” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 43–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Jones, A. Sebba, J. Gu et al., “Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 88–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Gabay, P. Emery, R. van Vollenhoven et al., “Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial,” The Lancet, vol. 381, no. 9877, pp. 1541–1550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. G. J. D. Bergman, M. C. Hochberg, M. Boers, N. Wintfeld, A. Kielhorn, and J. P. Jansen, “Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs,” Seminars in Arthritis and Rheumatism, vol. 39, no. 6, pp. 425–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Turkstra, S.-K. Ng, and P. A. Scuffham, “A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis,” Current Medical Research and Opinion, vol. 27, no. 10, pp. 1885–1897, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Pierreisnard, N. Issa, T. Barnetche, C. Richez, and T. Schaeverbeke, “Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate,” Joint Bone Spine, vol. 80, no. 4, pp. 386–392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Gallego-Galisteo, A. Villa-Rubio, E. Alegre-Del Rey, E. Márquez-Fernández, and J. J. Ramos-Báez, “Indirect comparison of biological treatments in refractory rheumatoid arthritis,” Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 3, pp. 301–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. C. Leffers, M. Østergaard, B. Glintborg et al., “Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry,” Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1216–1222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Nakashima, M. Kondo, T. Fukuda et al., “Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data,” Modern Rheumatology, vol. 24, pp. 258–264, 2014. View at Google Scholar
  22. G. R. Burmester, E. Feist, H. Kellner, J. Braun, C. Iking-Konert, and A. Rubbert-Roth, “Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA),” Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 755–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Yoshida, Y. Tokuda, H. Oshikawa et al., “An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety,” Rheumatology, vol. 50, no. 11, pp. 2093–2099, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. S. Smolen and D. Aletaha, “Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 43–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Canhão, A. Faustino, F. Martins, and J. E. Fonseca, “Reuma. PT—the rheumatic diseases portuguese register,” Acta Reumatologica Portuguesa, vol. 36, no. 1, pp. 45–56, 2011. View at Google Scholar · View at Scopus
  26. N. Takahashi, T. Kojima, A. Kaneko et al., “Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity,” Clinical Rheumatology, vol. 33, no. 1, pp. 39–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth et al., “Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial,” The Lancet, vol. 371, no. 9617, pp. 987–997, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Emery, E. Keystone, H. P. Tony et al., “IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial,” Annals of the Rheumatic Diseases, vol. 67, no. 11, pp. 1516–1523, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Hirabayashi and T. Ishii, “The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab,” Clinical Rheumatology, vol. 32, no. 1, pp. 123–127, 2013. View at Publisher · View at Google Scholar · View at Scopus